These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 21920019)

  • 21. Regional Social Vulnerability is Associated With Geographic Disparity in Waitlist Outcomes for Patients With Non-Hepatocellular Carcinoma Model for End-stage Liver Disease Exceptions in the United States.
    Cannon RM; Goldberg DS; Sheikh SS; Anderson DJ; Pozo M; Rabbani U; Locke JE
    Ann Surg; 2024 May; 279(5):825-831. PubMed ID: 37753656
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Disparities in Eurotransplant liver transplantation wait-list outcome between patients with and without model for end-stage liver disease exceptions.
    Umgelter A; Hapfelmeier A; Kopp W; van Rosmalen M; Rogiers X; Guba M;
    Liver Transpl; 2017 Oct; 23(10):1256-1265. PubMed ID: 28650098
    [TBL] [Abstract][Full Text] [Related]  

  • 23. MELDEQ : An alternative Model for End-Stage Liver Disease score for patients with hepatocellular carcinoma.
    Marvin MR; Ferguson N; Cannon RM; Jones CM; Brock GN
    Liver Transpl; 2015 May; 21(5):612-22. PubMed ID: 25694099
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Increasing Liver Transplantation Wait-List Dropout for Hepatocellular Carcinoma With Widening Geographical Disparities: Implications for Organ Allocation.
    Mehta N; Dodge JL; Hirose R; Roberts JP; Yao FY
    Liver Transpl; 2018 Oct; 24(10):1346-1356. PubMed ID: 30067889
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Predictors of low risk for dropout from the liver transplant waiting list for hepatocellular carcinoma in long wait time regions: Implications for organ allocation.
    Mehta N; Dodge JL; Hirose R; Roberts JP; Yao FY
    Am J Transplant; 2019 Aug; 19(8):2210-2218. PubMed ID: 30861298
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Model for end-stage liver disease exceptions in the context of the French model for end-stage liver disease score-based liver allocation system.
    Francoz C; Belghiti J; Castaing D; Chazouillères O; Duclos-Vallée JC; Duvoux C; Lerut J; Le Treut YP; Moreau R; Mandot A; Pageaux G; Samuel D; Thabut D; Valla D; Durand F
    Liver Transpl; 2011 Oct; 17(10):1137-51. PubMed ID: 21695771
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A new priority policy for patients with hepatocellular carcinoma awaiting liver transplantation within the model for end-stage liver disease system.
    Piscaglia F; Camaggi V; Ravaioli M; Grazi GL; Zanello M; Leoni S; Ballardini G; Cavrini G; Pinna AD; Bolondi L
    Liver Transpl; 2007 Jun; 13(6):857-66. PubMed ID: 17539006
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nonstandard Exception Requests Impact Outcomes for Pediatric Liver Transplant Candidates.
    Braun HJ; Perito ER; Dodge JL; Rhee S; Roberts JP
    Am J Transplant; 2016 Nov; 16(11):3181-3191. PubMed ID: 27214757
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Delayed hepatocellular carcinoma model for end-stage liver disease exception score improves disparity in access to liver transplant in the United States.
    Heimbach JK; Hirose R; Stock PG; Schladt DP; Xiong H; Liu J; Olthoff KM; Harper A; Snyder JJ; Israni AK; Kasiske BL; Kim WR
    Hepatology; 2015 May; 61(5):1643-50. PubMed ID: 25644186
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Access to Liver Transplantation in Different ABO-Blood Groups and "Exceptions Points" in a Model for End-Stage Liver Disease Allocation System: A Brazilian Single-Center Study.
    Martino RB; Waisberg DR; Dias APM; Inoue VBS; Arantes RM; Haddad LBP; Rocha-Santos V; Pinheiro RSN; Nacif LS; D'Albuquerque LAC
    Transplant Proc; 2018 Apr; 50(3):754-757. PubMed ID: 29661430
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Waitlist Outcomes in Liver Transplant Candidates with High MELD and Severe Hepatic Encephalopathy.
    Gadiparthi C; Cholankeril G; Yoo ER; Hu M; Wong RJ; Ahmed A
    Dig Dis Sci; 2018 Jun; 63(6):1647-1653. PubMed ID: 29611079
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Outcomes for liver transplant candidates listed with low model for end-stage liver disease score.
    Kwong AJ; Lai JC; Dodge JL; Roberts JP
    Liver Transpl; 2015 Nov; 21(11):1403-9. PubMed ID: 26289624
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Characterizing the Risk of False-Positive Hepatocellular Carcinoma in Recipients Transplanted With T2 MELD Exceptions.
    Bittermann T; Goldberg DS; Bauer CM; Khungar V
    Transplantation; 2017 May; 101(5):1099-1105. PubMed ID: 28121908
    [TBL] [Abstract][Full Text] [Related]  

  • 34. HEPATOCELLULAR CARCINOMA PATIENTS ARE ADVANTAGED IN THE CURRENT BRAZILIAN LIVER TRANSPLANT ALLOCATION SYSTEM. A COMPETING RISK ANALYSIS.
    Rodríguez S; Fleck AM; Mucenic M; Marroni C; Brandão A
    Arq Gastroenterol; 2020; 57(1):19-23. PubMed ID: 32294731
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Quantifying Sex-Based Disparities in Liver Allocation.
    Locke JE; Shelton BA; Olthoff KM; Pomfret EA; Forde KA; Sawinski D; Gray M; Ascher NL
    JAMA Surg; 2020 Jul; 155(7):e201129. PubMed ID: 32432699
    [TBL] [Abstract][Full Text] [Related]  

  • 36. United Network for Organ Sharing regional variations in appeal denial rates with non-standard Model for End-Stage Liver Disease/Pediatric End-Stage Liver Disease exceptions: support for a national review board.
    Gish RG; Wong RJ; Honerkamp-Smith G; Xu R; Osorio RW
    Clin Transplant; 2015 Jun; 29(6):513-22. PubMed ID: 25808918
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Waiting list removal rates among patients with chronic and malignant liver diseases.
    Freeman RB; Edwards EB; Harper AM
    Am J Transplant; 2006 Jun; 6(6):1416-21. PubMed ID: 16686765
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lower rates of receiving model for end-stage liver disease exception and longer time to transplant among nonalcoholic steatohepatitis hepatocellular carcinoma.
    Young K; Aguilar M; Gish R; Younossi Z; Saab S; Bhuket T; Liu B; Ahmed A; Wong RJ
    Liver Transpl; 2016 Oct; 22(10):1356-66. PubMed ID: 27348270
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Testing liver allocation in São Paulo, Brazil: the relationship of model for end-stage liver disease implementation with a reduction in waiting-list mortality.
    Salvalaggio PR; Afonso RC; Pereira LA; Ferraz-Neto BH
    Transplant Proc; 2012 Oct; 44(8):2283-5. PubMed ID: 23026574
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Liver Transplant Waitlist Outcomes and the Allocation of Hepatocellular Carcinoma Model for End-Stage Liver Disease Exception Points at a Low-Volume Center.
    Tan EK; Goh BKP; Lee SY; Krishnamoorthy TL; Tan CK; Jeyaraj PR
    Transplant Proc; 2018 Dec; 50(10):3564-3570. PubMed ID: 30577239
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.